These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 5851899)

  • 1. [Excretion of phenolic amines by patients with liver cirrhosis].
    Dubovský J; Petrásek J
    Cas Lek Cesk; 1965 Oct; 104(43):1183-5. PubMed ID: 5851899
    [No Abstract]   [Full Text] [Related]  

  • 2. Excretion of phenolic amines by patients with cirrhosis of the liver.
    Dubovský J; Petrásek J
    Rev Czech Med; 1966; 12(2):98-102. PubMed ID: 5941428
    [No Abstract]   [Full Text] [Related]  

  • 3. [Endogenous catecholamines and indolalkylamines in attacks of bronchial asthma and decompensated hepatic cirrhosis].
    Mihai C; Păuşescu E; Chirvasie R
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1976; 28(2):131-8. PubMed ID: 4871
    [No Abstract]   [Full Text] [Related]  

  • 4. [Elimination of triamterene, an antikaliuretic, and its phenolic metabolite, 2,4,7-triamino-6-p-hydroxyphenylpteridine, in the urine of subjects with normal liver function and in subjects suffering from liver cirrhosis].
    Andrasch H; Fink T; Schmid E
    Z Gastroenterol; 1971; 9(4):240-5. PubMed ID: 5164739
    [No Abstract]   [Full Text] [Related]  

  • 5. Aspects of catecholamine metabolism in hepatic cirrhosis.
    Banno0 S; Buzzetti A
    Policlinico Med; 1966 Dec; 73(6):376-86. PubMed ID: 5998806
    [No Abstract]   [Full Text] [Related]  

  • 6. [Increase of urinary elimination of catecholamines (adrenaline and noradrenaline) and of 3-methoxy-4-hydroxy-mandelic acid (MVA) in cirrhotic subjects].
    Le Moli S; Pagliaro L; Giglio G; Citarrella P
    Boll Soc Ital Biol Sper; 1964 Nov; 40(22):1407-10. PubMed ID: 5876859
    [No Abstract]   [Full Text] [Related]  

  • 7. Cerebrospinal fluid-, blood-, and ascitis-catecholamines in hepatic cirrhosis.
    Ciplea A; Bubuianu E
    Physiologie; 1979; 16(1):19-24. PubMed ID: 106413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased thromboxane metabolites excretion in liver cirrhosis.
    Davì G; Ferro D; Basili S; Iuliano L; Camastra C; Giammarresi C; Santarone S; Rocca B; Landolfi R; Ciabattoni G; Cordova C; Violi F
    Thromb Haemost; 1998 Apr; 79(4):747-51. PubMed ID: 9569186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Some aspects of catecholamine metabolism and its disorders in blood circulation disorders].
    Pocheptsov VG; Telegina ND
    Ter Arkh; 1971 Jan; 43(1):9-14. PubMed ID: 4930115
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on urinary phenolic compounds in man. II. Phenolic-acids and -amines during a load of alpha-methyl-dopa and disulfiram in periodic catatonia.
    Gjessing LR
    Scand J Clin Lab Invest; 1965; 17(6):549-57. PubMed ID: 5858748
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in acidic glycosaminoglycan components at different stages of human liver cirrhosis.
    Murata K; Akashio K; Ochiai Y
    Hepatogastroenterology; 1984 Dec; 31(6):261-5. PubMed ID: 6440847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous nitric oxide production is augmented as the severity advances in patients with liver cirrhosis.
    Hori N; Okanoue T; Mori T; Kashima K; Nishimura M; Nanbu A; Yoshimura M; Takahashi H
    Clin Exp Pharmacol Physiol; 1996 Jan; 23(1):30-5. PubMed ID: 8713493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tyrosiluria in liver cirrhosis].
    Dubovský J; Dubovská E
    Cesk Gastroenterol Vyz; 1965 Sep; 19(6):325-30. PubMed ID: 5854346
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pathogenesis of hepatic coma].
    Capocaccia L; Rossi Fanelli F; Cascino A; Cangiano C; Calcaterra V; de Conciliis D; Gentile S; Merli M; Riggio O; Stortoni M; Giunchi G
    Recenti Prog Med; 1981 Apr; 70(4):358-99. PubMed ID: 6114522
    [No Abstract]   [Full Text] [Related]  

  • 15. The metabolism of riboflavin in female patients with liver cirrhosis.
    Zempleni J; Galloway JR; McCormick DB
    Int J Vitam Nutr Res; 1996; 66(3):237-43. PubMed ID: 8899458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
    Staib AH; Schuppan D; Lissner R; Zilly W; von Bomhard G; Richter E
    Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of renal kallikrein in the derangement of sodium and water excretion in cirrhotic patients.
    Hattori K; Hasumura Y; Takeuchi J
    Scand J Gastroenterol; 1984 Sep; 19(6):844-8. PubMed ID: 6393317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of liver disease on urine caffeine metabolite ratios.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arachidonic acid derivatives and renal function in liver cirrhosis.
    Laffi G; La Villa G; Pinzani M; Marra F; Gentilini P
    Semin Nephrol; 1997 Nov; 17(6):530-48. PubMed ID: 9353864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortisone and ACTH in hepatitis and liver cirrhosis. The 17-ketosteroid excretion in cirrhosis of the liver.
    BIRKE G
    Acta Med Scand Suppl; 1953; 287():40-1. PubMed ID: 13137965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.